The FDA has granted fast track designation to Zimura for the treatment of geographic atrophy secondary to dry age-related macular degeneration, Iveric bio announced in a press release.
Zimura (avacincaptad pegol), a novel complement C5 inhibitor, has shown positive results in a clinical trial and was generally well tolerated after 12 months of administration, the release said.
“With no treatment options available for patients with geographic atrophy secondary to dry age-related macular degeneration, the FDA’s fast track designation recognizes the potential of Zimura to address this
Uncategorized